HDAC9 and Miyoshi myopathy: Over the past decade, patients with MM are living longer and better due to the introduction of several classes of drugs recently approved in the treatment of MM, which include the immunomodulators (thalidomide, lenalidomide, and pomalidomide), proteasome inhibitors (bortezomib, carfilzomib, and ixazomib), and the histone deacetylase (HDAC) blocker panobinostat [1–3].